Chronic lymphocytic leukemia/small lymphocytic lymphoma

Cover Page

Cite item

Full Text

Abstract

Chronic lymphocytic leukemia/small lymphocytic lymphoma. Clinical recommendations

About the authors

E. A. Nikitin

Botkin City Clinical Hospital

Author for correspondence.
Email: or@hpmp.ru

D. Sci. (Med.), Prof., Botkin City Clinical Hospital

Russian Federation, Moscow

T. E. Bialik

Sechenov First Moscow State Medical University (Sechenov University)

Email: or@hpmp.ru
Russian Federation, Moscow

A. Iu. Zaritskii

Almazov National Medical Research Centre

Email: or@hpmp.ru

D. Sci. (Med.), Prof., Almazov National Medical Research Centre

Russian Federation, Saint Petersburg

L. Iseber

Toulouse Cancer Center

Email: or@hpmp.ru

Prof., Toulouse Cancer Center, France

France, Toulouse

K. D. Kaplanov

Volgograd Regional Clinical Oncological Dispensary; Volgograd State Medical University

Email: or@hpmp.ru

Cand. Sci. (Med.), Volgograd Regional Clinical Oncological Dispensary, Volgograd State Medical University

Russian Federation, Volgograd

T. N. Lopatkina

Sechenov First Moscow State Medical University (Sechenov University)

Email: or@hpmp.ru

Cand. Sci. (Med.), Sechenov First Moscow State Medical University (Sechenov University)

Russian Federation, Moscow

S. A. Lugovskaia

Russian Medical Academy of Continuous Professional Education

Email: or@hpmp.ru

D. Sci. (Med.), Prof., Russian Medical Academy of Continuous Professional Education

Russian Federation, Moscow

O. V. Mukhortova

Bakulev National Medical Research Center for Cardiovascular Surgery

Email: or@hpmp.ru

D. Sci. (Med.), Bakulev National Medical Research Center for Cardiovascular Surgery

Russian Federation, Moscow

E. A. Osmanov

Sechenov First Moscow State Medical University (Sechenov University); Blokhin National Medical Research Center of Oncology

Email: or@hpmp.ru

D. Sci. (Med.), Prof., Blokhin National Medical Research Center of Oncology, Sechenov First Moscow State Medical University (Sechenov University)

Russian Federation, Moscow

I. V. Poddubnaya

Volgograd State Medical University

Email: or@hpmp.ru
ORCID iD: 0000-0002-0995-1801

D. Sci. (Med.), Prof., Acad. RAS, Russian Medical Academy of Continuous Professional Education

Russian Federation, Volgograd

O. S. Samoilova

Semashko Nizhny Novgorod Regional Clinical Hospital

Email: or@hpmp.ru

Cand. Sci. (Med.), Semashko Nizhny Novgorod Regional Clinical Hospital

Russian Federation, Nizhny Novgorod

E. A. Stadnik

Almazov National Medical Research Centre; Pavlov First Saint Petersburg State Medical University

Email: or@hpmp.ru

Cand. Sci. (Med.), Pavlov First Saint Petersburg State Medical University, Almazov National Medical Research Centre

Russian Federation, Saint Petersburg

N. A. Falaleeva

Tsyba Medical Radiological Scientific Center – branch of the National Medical Research Center for Radiology

Email: or@hpmp.ru

D. Sci. (Med.), Tsyba Medical Radiological Scientific Center – branch of the National Medical Research Center for Radiology

Russian Federation, Moscow

V. V. Baikov

Pavlov First Saint Petersburg State Medical University

Email: or@hpmp.ru

D. Sci. (Med.), Prof., Pavlov First Saint Petersburg State Medical University

Russian Federation, Saint Petersburg

A. M. Kovrigina

Academy of Postgraduate Education; National Research Center for Hematology

Email: or@hpmp.ru

D. Sci. (Biol.), Prof., Academy of Postgraduate Education, National Research Center for Hematology

Russian Federation, Moscow

A. A. Nevol’skikh

Tsyba Medical Radiological Scientific Center – branch of the National Medical Research Center for Radiology

Email: or@hpmp.ru

D. Sci. (Med.), Tsyba Medical Radiological Scientific Center – branch of the National Medical Research Center for Radiology

Russian Federation, Moscow

S. A. Ivanov

Tsyba Medical Radiological Scientific Center – branch of the National Medical Research Center for Radiology

Email: or@hpmp.ru

D. Sci. (Med.), Prof. RAS, Tsyba Medical Radiological Scientific Center – branch of the National Medical Research Center for Radiology

Russian Federation, Moscow

Zh. V. Khailova

Tsyba Medical Radiological Scientific Center – branch of the National Medical Research Center for Radiology

Email: or@hpmp.ru

Cand. Sci. (Med.), Tsyba Medical Radiological Scientific Center – branch of the National Medical Research Center for Radiology

Russian Federation, Moscow

T. G. Gevorkian

Blokhin National Medical Research Center of Oncology

Email: or@hpmp.ru

deputy director, Blokhin National Medical Research Center of Oncology

Russian Federation, Moscow

References

  1. Packham G, Stevenson F. The role of the B-cell receptor in the pathogenesis of chronic lymphocytic leukaemia. Semin Cancer Biol 2010; 20 (6): 391–9.
  2. Vardi A et al. Immunogenetic studies of chronic lymphocytic leukemia: Revelations and speculations about ontogeny and clinical evolution. Cancer Res 2014; 74 (16): 4211–6.
  3. Murray F et al. Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: Implications for the role of antigen selection in leukemogenesis. Blood 2008; 111 (3): 1524–33.
  4. Strati P, Shanafelt T.D. Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: Diagnosis, natural history, and risk stratification. Blood. Am Soc Hematol 2015; 126 (4): 454–62.
  5. Zhang S, Kipps TJ. The Pathogenesis of Chronic Lymphocytic Leukemia. Annu Rev Pathol Mech Dis 2014; 9 (1): 103–18.
  6. Burger JA, Chiorazzi N. B cell receptor signaling in chronic lymphocytic leukemia. Trends Immunol 2013; 34 (12): 592–601.
  7. Morton LM et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006; 107 (1): 265–76.
  8. Watson L, Wyld P, Catovsky D. Disease burden of chronic lymphocytic leukaemia within the European Union. Eur J Haematol 2008; 81 (4): 253–8.
  9. Jemal A et al. Cancer statistics, 2007. CA. Cancer J Clin 2007; 57 (1): 43–66.
  10. Dores GM et al. Chronic lymphocytic leukaemia and small lymphocytic lymphoma: Overview of the descriptive epidemiology. Br J Haematol 2007; 139 (5): 809–19.
  11. Злокачественные новообразования в России в 2017 году (заболеваемость и смертность). Под ред. А.Д.Каприна, В.В.Старинского, Г.В.Петровой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2018.
  12. [Malignant neoplasms in Russia in 2017 (morbidity and mortality). Pod red. A.D.Kaprina, V.V.Starinskogo, G.V.Petrovoi. Moscow: MNIOI im. P.A. Gertsena – filial FGBU «NMITs radiologii» Minzdrava Rossii, 2018 (in Russian).]
  13. Hallek M et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood 2018; 131 (25): 2745–60.
  14. Armitage J.O. Staging Non-Hodgkin Lymphoma. CA. Cancer J Clin. Wiley 2005; 55 (6): 368–76.
  15. An international prognostic index for patients with chronic lymphocytic leukaemia ¬(CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol 2016; 17 (6): 779–90.
  16. Swerdlow SH et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016.
  17. Никитин Е.А. и др. Хронический лимфолейкоз. Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний. Под ред. И.В.Поддубной, В.Г.Савченко. 2018; с. 179–200.
  18. [Nikitin E.A. et al. Khronicheskii limfoleikoz. Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniiu zlokachestvennykh limfoproliferativnykh zabolevanii. Pod red. I.V.Poddubnoi, V.G.Savchenko. 2018; p. 179–200 (in Russian).]
  19. Morice WG et al. Predictive value of blood and bone marrow flow cytometry in B-cell lymphoma classification: Comparative analysis of flow cytometry and tissue biopsy in 252 patients. Mayo Clin Proc 2008; 83 (7): 776–85.
  20. Rawstron AC et al. Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. N Engl J Med 2008; 359 (6): 575–83.
  21. Molica S, Giannarelli D, Montserrat E. Minimal Residual Disease and Survival Outcomes in Patients With Chronic Lymphocytic Leukemia: A Systematic Review and Meta-analysis. Clin Lymphoma Myeloma Leuk 2019; 19 (7): 423–30.
  22. Rossi D et al. Occult hepatitis B virus infection of peripheral blood mononuclear cells among treatment-naïve patients with chronic lymphocytic leukemia. Leuk Lymphoma 2009; 50 (4): 604–11.
  23. Conte MJ et al. Use of positron emission tomography- computed tomography in the management of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Leuk Lymphoma Informa Healthcare 2014; 55 (9): 2079–84.
  24. Parikh SA, Kay NE, Shanafelt TD. How we treat Richter syndrome. Blood 2014; 123 (11): 1647–57.
  25. Hallek M et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open-label, phase 3 trial. Lancet 2010; 376 (9747): 1164–74.
  26. Fischer K et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: Updated results of the CLL8 trial. Blood 2016; 127 (2): 208–15.
  27. Fischer K et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: A multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2012; 30 (26): 3209–16.
  28. Eichhorst B et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol 2016; 17 (7): 928–42.
  29. Shanafelt T, Wang V, Kay N. A randomized phase III study of ibrutinib (PCI-32765)-based therapy vs. standard fludarabine, cyclophosphamide, and rituximab (FCR) chemoimmunotherapy in untreated younger patients with chronic lymphocytic leukemia (CLL): a trial of the ECOG-ACRIN Cancer. ASH Annual Meeting. 2018. P. LBA-4.
  30. Burger JA et al. Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. Blood 2019; 133 (10): 1011–9.
  31. National Comprehensive Cancer Network. NCCN Practice Guidelines in Oncology. Chronic Lymphocytic Leukemia. Small Lymphocytic Lymphoma. 2019.
  32. Assouline S et al. Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia ¬(SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial. Lancet Haematol 2016; 3 (3): e128–38.
  33. Goede V et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 2014; 370 (12): 1101–10.
  34. Michallet AS et al. Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: Primary analysis of the randomized, open-label mable study. Haematologica. Ferrata Storti Foundation 2018; 103 (4): 698–706.
  35. Burger JA et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med 2015; 373 (25): 2425–37.
  36. Burger JA et al. Ibrutinib for First-Line Treatment of Older Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): A 4-Year Experience From the REASONATE-2 Study. EHA 23 Proceedings. 2018. P. Abstract PF343.
  37. Woyach JA et al. Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. N Engl J Med 2018; 379 (26): 2517–28.
  38. Nikitin E. Randomised Comparison Of FCR-Lite And ClbR (Chlorambucil Plus Rituximab) Regimens In Elderly Patients With Chronic Lymphocytic Leukemia. EHA 18 Proceedings. 2013. P. Abstract NS1147.
  39. Foà R et al. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients. Am J Hematol 2014; 89 (5): 480–6.
  40. Hillmen P et al. Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: Final analysis of an open-label phase II study. J Clin Oncol 2014; 32 (12): 1236–41.
  41. Fischer K et al. Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. N Engl J Med 2019; 380 (23): 2225–36.
  42. Jones JA et al. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol 2018; 19 (1): 65–75.
  43. Catovsky D, Else M, Richards S. Chlorambucil-still not bad: A reappraisal. Clin Lymphoma 2011; 11 (Suppl. 1): S2.
  44. Hainsworth JD et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: A phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2003; 21 (9): 1746–51.
  45. Michallet A-S et al. Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: A real-world experience of 71 patients treated in France: A study from the French Innovative Leukemia Organization (FILO) group. Am J Hematol 2017; 92 (6): E105–E107.
  46. Burger JA et al. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: A single-arm, phase 2 study. Lancet Oncol 2014; 15 (10): 1090–9.
  47. Sorror ML et al. Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. J Clin Oncol 2008; 26 (30): 4912–20.
  48. Dreger P et al. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: Long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood 2010; 116 (14): 2438–47.
  49. Stilgenbauer S et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol 2016; 17 (6): 768–78.
  50. Tam CS et al. Life After FCR: Outcomes of patients with chronic lymphocytic leukemia who progress after frontline treatment with Fludarabine, Cyclophosphamide and Rituximab. Blood 2014; 3059–64.
  51. Fischer K et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: A Multicenter Phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2011; 29 (26): 3559–66.
  52. Byrd JC et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 2014; 371 (3): 213–23.
  53. Moreno C et al. Ibrutinib in previously treated chronic lymphocytic leukemia: updated efficacy and safety of the RESONATE study with up to four years of follow-up. EHA 22 Proceedings. 2017. P. Abstract S769.
  54. Chanan-Khan A et al. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): A randomised, double-blind, phase 3 study. Lancet Oncol 2016; 17 (2): 200–11.
  55. Hallek M et al. Three-year follow-up of patients with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) receiving ibrutinib plus bendamustine and rituximab (BR) versus placebo plus BR: an update of the HELIOS study. Leuk Lymphoma 2017; 58: 192–4.
  56. Seymour JF et al. Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. N Engl J Med 2018; 378 (12): 1107–20.
  57. Castro JE et al. Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia. Leukemia 2009; 23 (10): 1779–89.
  58. Raanani P et al. Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta-analysis. Leuk Lymphoma 2009; 50 (5): 764–72.
  59. Константинова Т.С., Клясова Г.А., Капланов К.Д. Лечение и профилактика инфекционных осложнений у пациентов с лимфопролиферативными заболеваниями. Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний. Под ред. И.В.Поддубной, В.Г.Савченко. 2018; с. 289–311.
  60. [Konstantinova T.S., Kliasova G.A., Kaplanov K.D. Lechenie i profilaktika infektsionnykh oslozhnenii u patsientov s limfoproliferativnymi zabolevaniiami. Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniiu zlokachestvennykh limfoproliferativnykh zabolevanii. Pod red. I.V.Poddubnoy, V.G.Savchenko. 2018; p. 289–311 (in Russian).]
  61. Rubin LG et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2014; 58 (3): 309–18.
  62. Sinisalo M et al. Response to vaccination against different types of antigens in patients with chronic lymphocytic leukaemia. Br J Haematol 2001; 114 (1): 107–10.
  63. Абузарова Г.Р. и др. Обезболивание взрослых и детей при оказании медицинской помощи. Методические рекомендации. ФГБОУ ВО РНИМУ им. Н.И.Пирогова Минздрава России, 2016.
  64. [Abuzarova G.R. et al. Obezbolivanie vzroslykh i detei pri okazanii meditsinskoi pomoshchi. Metodicheskie rekomendatsii. FGBOU VO RNIMU im. N.I.Pirogova Minzdrava Rossii, 2016 (in Russian).]
  65. Абузарова Г.Р. Лечение болевого синдрома у онкологических больных. Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний. Под ред. И.В.Поддубной, В.Г.Савченко. 2018; с. 278–88.
  66. [Abuzarova G.R. Lechenie bolevogo sindroma u onkologicheskikh bol’nykh. Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniiu zlokachestvennykh limfoproliferativnykh zabolevanii. Pod red. I.V.Poddubnoy, V.G.Savchenko. 2018; p. 278–88 (in Russian).]
  67. Paul KL. Rehabilitation and exercise considerations in hematologic malignancies. Am J Phys Med Rehabil 2011; 90 (5 Suppl. 1): S88–94.
  68. Reda G et al. Secondary Malignancies in Chronic Lymphocytic Leukemia: A Single Centre Retrospective Analysis of 514 Cases. Blood 2015; 126 (23).
  69. Beiggi S et al. Increased risk of second malignancies in chronic lymphocytic leukaemia patients as compared with follicular lymphoma patients: a Canadian population-based study. Br J Cancer 2013; 109 (5): 1287–90.
  70. Oken MM et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5 (6): 649–55.
  71. Linn BS, Linn MW, Gurel L. Cumulative illness rating scale. J Am Geriatr Soc 1968; 16 (5): 622–6.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Annex B1-B2

Download (1MB)
Indexing metadata

Copyright (c) 2020 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 


Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).